<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04434170</url>
  </required_header>
  <id_info>
    <org_study_id>Entresto CPET</org_study_id>
    <nct_id>NCT04434170</nct_id>
  </id_info>
  <brief_title>Effects of Sacubitril/Valsartan on Exercise Capacity, Natriuretic Peptides and Ventricular Remodeling in Heart Failure</brief_title>
  <official_title>Valutazione Della capacità d'Esercizio, Della funzionalità Respiratoria e Del Rimodellamento Ventricolare Sinistro in Pazienti Affetti da Scompenso Cardiaco a Frazione d'Eiezione Ridotta Trattati Con Sacubitril/Valsartan</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centro Cardiologico Monzino</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centro Cardiologico Monzino</source>
  <oversight_info>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Background: Sacubitril/valsartan, a novel therapy in the treatment of heart failure with&#xD;
      reduced ejection fraction (HFrEF), has recently proved efficacy in improving exercise&#xD;
      tolerance and cardiac performance. Cardiopulmonary exercise test (CPET) provides functional&#xD;
      prognostic parameters for patient with HFrEF (i.e. peakVO2 and ventilation/CO2 production&#xD;
      [VE/VCO2] slope) and it is a well-recognized, valuable, accurate tool for risk&#xD;
      stratification.&#xD;
&#xD;
      Aim of the study and methods: The aim of the study is to prospectively enroll a cohort of 100&#xD;
      HFrEF outpatients eligible for sacubitril/valsartan and perform serial CPET, laboratory and&#xD;
      echocardiographic assessments before and during the gradual titration of the treatment, in&#xD;
      order to evaluate its effects on cardiopulmonary function and left ventricular remodeling.&#xD;
      The procedures will be repeated along the follow-up at 1, 2 and 3 months after the enrollment&#xD;
      (titration period) and at 6 months after the reach of the maximum tolerated dose.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Given the recent introduction of the drug into the clinical routine, the evaluation of the&#xD;
      experience &quot;on the field&quot; is important to refine the clinical management of patients treated&#xD;
      with sacubitril / valsartan. Furthermore, at the moment sacubitril / valsartan has proven&#xD;
      effective in some small preliminary studies in improving the ejection fraction and some&#xD;
      echocardiographic parameters of ventricular remodeling on top of the concomitant optimal&#xD;
      medical therapy, although further data are needed in this regard.&#xD;
&#xD;
      In particular, the potential benefits on exercise capacity, respiratory function parameters&#xD;
      and left ventricular remodeling in heart failure patients treated with sacubitril / valsartan&#xD;
      has not been studied extensively at the moment. In this regard, the cardiopulmonary exercise&#xD;
      test (CPET) allows to obtain prognostic functional parameters in patients with chronic heart&#xD;
      failure such as peak V02 (peak V02) and the ventilation / production of C02 slope (VE / VC02&#xD;
      slope). CPET is a valid, recognized and accurate tool for risk stratification in heart&#xD;
      failure patients.&#xD;
&#xD;
      Furthermore, few data are available on lung diffusion (DLCO) and on specific markers of the&#xD;
      alveolar-capillary membrane, such as type B surfactant proteins (SPB) in patients treated&#xD;
      with sacubtril / valsartan. Our team has already shown how these biomarkers and DLCO are&#xD;
      influenced by drug treatments such as Levosimendan and Ace inhibitors.&#xD;
&#xD;
      The aim of the study is to evaluate the exercise capacity, spirometry, echocardiographic&#xD;
      parameters of left ventricular sistolic and diastolic function, Nt-proBNP dosage and quality&#xD;
      of life and the related dose-effect correlation in a multicenter cohort of 100 patients with&#xD;
      stable heart failure (class functional NYHA II e lII) and reduced left ventricular ejection&#xD;
      fraction in patients eligible for sacubitril / valsartan treatment.&#xD;
&#xD;
      A subgroup of patients will be also analyzed for data relating to the effect of sacubitril /&#xD;
      valsartan on DLCO and blood levels of Surfactant Bindig protein (SPB).&#xD;
&#xD;
      Sacubitril / Valsartan will be prescribed according to guidelines, initially at the lowest&#xD;
      dosage of 24/26 mg b.i.d. to verify its tolerability with the prospect of gradually&#xD;
      increasing the dosage during subsequent follow-up visits. The re-evaluation of the treatment&#xD;
      and the titration of the sacubitril / valsartan dose will take place every 4 weeks until the&#xD;
      maximum tolerated dose is reached. The dose under study will be the maximum tolerated by the&#xD;
      patient (however not higher than 97 mg / 103mg bd).&#xD;
&#xD;
      Cardiological examination with ECG, spirometry, CPET, the Kansas City Cardiomyopathy&#xD;
      Questionnaire, blood count, creatinine, nitrogen, sodium, potassium, chlorine and NTproBNP&#xD;
      will be performed at each visit (from Baseline to 6 months). The colordoppler echocardiogram&#xD;
      will instead be performed only at the baseline and after 6 months.&#xD;
&#xD;
      A subset of patients will also be subjected to analysis of the blood levels of SPB and DLCO&#xD;
      at baseline and 6 months after reaching the maximum tolerated dose.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 15, 2018</start_date>
  <completion_date type="Anticipated">September 15, 2021</completion_date>
  <primary_completion_date type="Actual">November 30, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>VO2 evaluation after treatment</measure>
    <time_frame>1 month after start of treatment with sacubitril/valsartan</time_frame>
    <description>changes in peak VO2 at cardiopulmonary exercise test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VO2 evaluation after treatment</measure>
    <time_frame>2 months after start of treatment with sacubitril/valsartan</time_frame>
    <description>changes in peak VO2 at cardiopulmonary exercise test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VO2 evaluation after treatment</measure>
    <time_frame>3 months after start of treatment with sacubitril/valsartan</time_frame>
    <description>changes in peak VO2 at cardiopulmonary exercise test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>VO2 evaluation after treatment</measure>
    <time_frame>9 months after start of treatment with sacubitril/valsartan</time_frame>
    <description>changes in peak VO2 at cardiopulmonary exercise test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>lung function evaluation after treatment</measure>
    <time_frame>1 month after start of treatment with sacubitril/valsartan</time_frame>
    <description>changes in FVC, FEV1, PEF and FEV1%, by spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lung function evaluation after treatment</measure>
    <time_frame>2 months after start of treatment with sacubitril/valsartan</time_frame>
    <description>changes in FVC, FEV1, PEF and FEV1%, by spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lung function evaluation after treatment</measure>
    <time_frame>3 months after start of treatment with sacubitril/valsartan</time_frame>
    <description>changes in FVC, FEV1, PEF and FEV1%, by spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>lung function evaluation after treatment</measure>
    <time_frame>9 months after start of treatment with sacubitril/valsartan</time_frame>
    <description>changes in FVC, FEV1, PEF and FEV1%, by spirometry</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLCO</measure>
    <time_frame>1 month after start of treatment with sacubitril/valsartan</time_frame>
    <description>DLCO evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>DLCO</measure>
    <time_frame>9 months after start of treatment with sacubitril/valsartan</time_frame>
    <description>DLCO evaluation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surfactant B-type protein after treatment</measure>
    <time_frame>1 month after start of treatment with sacubitril/valsartan</time_frame>
    <description>SPB quantification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Surfactant B-type protein after treatment</measure>
    <time_frame>9 months after start of treatment with sacubitril/valsartan</time_frame>
    <description>SPB quantification</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>left ventricular remodeling</measure>
    <time_frame>1 month after start of treatment with sacubitril/valsartan</time_frame>
    <description>ejection fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>left ventricular remodeling</measure>
    <time_frame>2 months after start of treatment with sacubitril/valsartan</time_frame>
    <description>ejection fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>left ventricular remodeling</measure>
    <time_frame>9 months after start of treatment with sacubitril/valsartan</time_frame>
    <description>ejection fraction</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>left ventricular remodeling</measure>
    <time_frame>1 month after start of treatment with sacubitril/valsartan</time_frame>
    <description>End-diastolic and end-systolic left ventricular volumes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>left ventricular remodeling</measure>
    <time_frame>2 months after start of treatment with sacubitril/valsartan</time_frame>
    <description>End-diastolic and end-systolic left ventricular volumes</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>left ventricular remodeling</measure>
    <time_frame>9 months after start of treatment with sacubitril/valsartan</time_frame>
    <description>End-diastolic and end-systolic left ventricular volumes</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Heart Failure</condition>
  <arm_group>
    <arm_group_label>Heart failure</arm_group_label>
    <description>outpatients with heart failure with reduced ejection fraction in treatment with sacubitril/valsartan according to guidelines</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Sacubitril-Valsartan</intervention_name>
    <description>outpatients who start treatment with sacubitril/valsartan according to guidelines will andergo cardiopulmonary exercise testing evaluation</description>
    <arm_group_label>Heart failure</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        HFrEF outpatients eligible for sacubitril/valsartan according to guidelines and perform&#xD;
        serial CPET, laboratory and echocardiographic assessments before and during the gradual&#xD;
        titration of the treatment&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  New York Heart Association Class (NYHA) II-III&#xD;
&#xD;
          -  stable clinical conditions&#xD;
&#xD;
          -  reduced ejection fraction (&lt; 35%)&#xD;
&#xD;
          -  capability to perform a cardiopulmonary exercise test (CPET)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  moderate-severe chronic obstructive pulmonary disease&#xD;
&#xD;
          -  chronic oxygen therapy&#xD;
&#xD;
          -  contraindication to CPET&#xD;
&#xD;
          -  planned procedures (i.e. cardiac surgery, revascularization procedures, CRT&#xD;
             implantation) that could per se impact on CPET, echocardiography and laboratory values&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Piergiuseppe Agostoni, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centro Cardiologico Monzino</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Centro Cardiologico Monzino</name>
      <address>
        <city>Milan</city>
        <zip>20138</zip>
        <country>Italy</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Italy</country>
  </location_countries>
  <verification_date>February 2021</verification_date>
  <study_first_submitted>June 4, 2020</study_first_submitted>
  <study_first_submitted_qc>June 12, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">June 16, 2020</study_first_posted>
  <last_update_submitted>February 3, 2021</last_update_submitted>
  <last_update_submitted_qc>February 3, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">February 4, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Centro Cardiologico Monzino</investigator_affiliation>
    <investigator_full_name>Piergiuseppe Agostoni</investigator_full_name>
    <investigator_title>Prof</investigator_title>
  </responsible_party>
  <keyword>sacubitril/valsartan</keyword>
  <keyword>exercise</keyword>
  <keyword>cardiopulmonary exercise test</keyword>
  <keyword>left ventricular remodeling</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Heart Failure</mesh_term>
    <mesh_term>Ventricular Remodeling</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Valsartan</mesh_term>
    <mesh_term>Sacubitril and valsartan sodium hydrate drug combination</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

